不同剂量阿托伐他汀钙短期应用对冠状动脉粥样硬化性心脏病患者血清 胆红素水平的影响

目的:探讨不同剂量阿托伐他汀钙短期应用对冠状动脉粥样硬化性心脏病患者血清胆红素水平的影响。方法:按照详细的纳入及排除标准的筛选共计264例冠状动脉粥样硬化性心脏病患者入选,分为20 mg和40 mg治疗剂量组,观察患者用药前后胆红素水平的变化水平的改变。结果:与服药前的相比,服用阿托伐他汀钙40 mg和20 mg的患者血清总胆红素、直接胆红素水平均呈显著性上升(P0.05),而间接胆红素水平差异无显著性。服药1个月后,40 mg组患者血清总胆红素、直接胆红素水平升高较20 mg组更显著(P0.05),但两组间接胆红素水平差异没有显著性。总胆红素变化率与患者胆固醇水平呈显著相关性,其20mg组为0.419,40 mg组为0.634(P0.001)。结论:阿托伐他汀钙治疗冠状动脉粥样硬化性心脏病患者可导致其血清总胆红素和直接胆红素水平升高,且高剂量较低剂量对总胆红素和直接胆红素的影响更明显。

Effect of Different Doses of Atorvastatin Calciumon the Level of Bilirubin in Patients with Coronary Heart Disease

Objective:To investigate the effect of short-term application of different doses of atorvastatin calcium on the serum bilirubin levels of patients with coronary atherosclerosis.Methods:A total of 264 cases of patients with coronary artery disease were selected and divided into 20 mg and 40 mg dose group, the changes of bilirubin level in patients before and after treatment were observed.Results:Compared with before treatment, the serum total bilirubin and direct bilirubin levels of both groups were significantly increased (P <0.05), while no significant difference was found in the indirect bilirubin level. After 1 month'' treatment, the serum total bilirubin and direct bilirubin levels of 40 mg group, increased more significantly than the 20 mg group (P<0.05), but no significant difference was found in the indirect bilirubin levels. The changes of total bilirubin was significant correlated with the cholesterol level in patients with coronary atherosclerosis (20 mg group: 0.419; 40 mg group: 0.634) (P<0.001).Conclusion:Atorvastatin calcium therapy could elevate the serum total bilirubin and direct bilirubin levels of patients with coronary artery disease and the effects of high doses of atorvastatin calciumon the total bilirubin and direct bilirubin levels was more obvious than low dose.